This Drug Could End H.I.V. Why Hasn’t It?
Listen now
Description
Dr. Robert Grant developed a treatment — a daily pill known as pre-exposure prophylaxis, or PrEP — that could stop the AIDS crisis. We look at why that hasn’t happened. Guests: Dr. Grant, who has been working on H.I.V. treatment and prevention for over 30 years, and Donald G. McNeil Jr., a science and health reporter for The New York Times. For more information on today’s episode, visit nytimes.com/thedaily. Background reading: Gilead Sciences, the maker of Truvada, the only drug approved to prevent H.I.V. infection, will donate enough of the drug to supply 200,000 patients, but critics questioned the company’s motives.The high cost of drugs remains a major obstacle to ending the AIDS epidemic.Here’s more information about PrEP from the Centers for Disease Control and Prevention website.
More Episodes
With crowds that are said to number 15,000 to 20,000 people, Senator Elizabeth Warren’s campaign events frequently dwarf those of her Democratic rivals. This week, we experienced the growing phenomenon that is the Warren rally. Guest: Thomas Kaplan, a political reporter for The New York Times....
Published 09/20/19
In Part 1 of this series, our colleagues Jodi Kantor and Megan Twohey reported on Lisa Bloom, a victims’ rights attorney who used her experience representing women to defend Harvey Weinstein. In Part 2, we look at the role of Ms. Bloom’s mother, the women’s rights lawyer Gloria Allred.  Guests:...
Published 09/19/19
Last week, our colleagues Jodi Kantor and Megan Twohey published a book documenting their investigation of Harvey Weinstein. In writing it, they discovered information about two feminist icons — Gloria Allred and her daughter, Lisa Bloom — that raises questions about their legacies and the legal...
Published 09/18/19